Interferon-β bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice

Abstract

Background

Neutralising antibodies (NAb) to interferon beta (IFNβ) are associated with a reduced bioactivity and efficacy of IFNβ in multiple sclerosis (MS). Unclear is how to apply IFNβ bioactivity measurements (quantification of Myxovirus resistance protein A (MxA) mRNA) in clinical practice.

Objectives

To evaluate value and feasibility of IFNβ bioactivity measurement with a single MxA mRNA measurement for screening and a second measurement before and after IFNβ administration for definite confirmation of IFNβ bioactivity status.

Methods

In 79 MS patients MxA mRNA expression was determined 4 hours after IFNβ administration. If inadequate, MxA mRNA expression testing was repeated 3 months afterwards, comparing post- and pre injection samples to determine whether IFNb bioactivity was persistently lacking. MxA mRNA expression was compared to NAβ titres, determined by the cytopathic effect assay (CPE).

Results

NAb titres correlated significantly with MxA mRNA expression and MxA mRNA induction. Of all screened patients, only one patient had adequate MxA mRNA expression and high NAb titres simultaneously. Of the biological non-responders at second measurement (21/55), 17 (81%) were high-titre NAb positive, 1 (5%) was low-titre NAb positive and 3 (14%) were NAb negative. Without considering the pre-injection measurement, two more NAb negative patients would have tested negative for IFNβ bioactivity, emphasizing the need of a pre-injection sample.

Conclusions

Our data suggest that for IFNβ bioactivity screening a single post-injection measurement seems reasonable. However, MxA induction measurement based on both pre- and post-IFNβ injection samples at second measurement is somewhat more precise in determining ultimate IFNβ bioactivity status.

Keywords

bioactivity clinical practice immune modulating therapy interferon β multiple sclerosis neutralising antibodies

Get full access to this article

View all access options for this article.

References

1 Sorensen PS Ross C Clemmesen KM . Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184–1191.

2 Ross C Clemmesen KM Svenson M . Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2005; 48: 706–712.

3 Sorensen PS Deisenhammer F Duda P . Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817–827.

4 Bertolotto A Gilli F Sala A . Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001; 256: 141–152.

5 Deisenhammer F Reindl M Harvey J Gasse T Dilitz E Berger T . Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239–1243.

6 Ross C Clemmesen KM Sorensen PS Koch-Henriksen N Bendtzen K . Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Mult Scler 2006; 12: 39–46.

7 Sorensen PS Koch-Henriksen N Ross C Clemmesen KM Bendtzen K . Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33–39.

8 Farrell RA Giovannoni G . Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis 2. Mult Scler 2007; 13: 567–577.

9 Bertolotto A Gilli F Sala A . Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003; 60: 634–639.

10.

10 Goodin DS Frohman EM Hurwitz B . Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977–984.

11.

11 Capra R Sottini A Cordioli C . IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. J Neuroimmunol 2007; 189: 102–110.

12.

12 Hoffmann LA Krumbholz M Faber H . Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies. Neurology 2007; 68: 958–959.

13.

13 Gilli F Marnetto F Caldano M . Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 2005; 158: 195–203.

14.

14 Antonelli G Currenti M Turriziani O Dianzani F . Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1999; 163: 882–885.

15.

15 Bertolotto A Sala A Caldano M . Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 2007; 321: 19–31.

16.

16 Grossberg SE Kawade Y Kohase M Klein JP . The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001; 21: 743–755.

17.

17 Kawade Y Finter N Grossberg SE . Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J Immunol Methods 2003; 278: 127–144.

18.

18 Sominanda A Hillert J Fogdell-Hahn A . In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent 1. J Neurol Neurosurg Psychiatry 2008; 79: 57–62.

19.

19 Bertolotto A Sala A Malucchi S . Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 2004; 75: 1294–1299.

20.

20 Malucchi S Sala A Gilli F . Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis 1. Neurology 2004; 62: 2031–2037.

21.

21 Perini P Calabrese M Biasi G Gallo P . The clinical impact of interferon beta antibodies in relapsing-remitting MS 1. J Neurol 2004; 251: 305–309.

22.

22 Petkau J White R . Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 1997; 3: 402.

23.

23 Polman CH Kappos L Petkau J Thompson A . Neutralising antibodies to interferon beta during the treatment of multiple sclerosis 1. J Neurol Neurosurg Psychiatry 2003; 74: 1162–1163.

24.

24 Rudick RA Simonian NA Alam JA . Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) 1. Neurology 1998; 50: 1266–1272.

25.

25 Sorensen PS Tscherning T Mathiesen HK . Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006; 67: 1681–1683.

26.

26 Malucchi S Gilli F Caldano M . Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008; 70: 1069–1070.